[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-06 Immune monitoring\/clinical correlates,,"},{"Key":"Keywords","Value":"Neoantigens,Immune response,Immune checkpoint blockade,Cancer vaccine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Mansi Saxena<sup>1<\/sup>, Jonathan Anker<sup>1<\/sup>, Julia Kodysh<sup>1<\/sup>, Timothy O'Donnell<sup>1<\/sup>, Marcia Meseck<sup>1<\/sup>, Olivia Hapanowicz<sup>1<\/sup>, Scot Niglio<sup>2<\/sup>, Hardik Shah<sup>3<\/sup>, Yayoi Kinoshita<sup>4<\/sup>, Rachel Brody<sup>4<\/sup>, Alex Rubinsteyn<sup>5<\/sup>, Robert Sebra<sup>3<\/sup>, <b>Nina Bhardwaj<\/b><sup>1<\/sup>, Mathew Galsky<sup>1<\/sup><br><br\/><sup>1<\/sup>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY,<sup>2<\/sup>NYU Langone Health, New York, NY,<sup>3<\/sup>Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY,<sup>4<\/sup>Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,<sup>5<\/sup>UNC School of Medicine, Chapel Hill, NC","CSlideId":"","ControlKey":"4765949d-9fa7-44f3-88f1-d693bd50727f","ControlNumber":"10787","DisclosureBlock":"&nbsp;<b>M. Saxena, <\/b> None..<br><b>J. Anker, <\/b> None..<br><b>J. Kodysh, <\/b> None..<br><b>T. O'Donnell, <\/b> None..<br><b>M. Meseck, <\/b> None..<br><b>O. Hapanowicz, <\/b> None.&nbsp;<br><b>S. Niglio, <\/b> <br><b>STEMCELL Technologies<\/b> Employment, An Immediate Family Member.<br><b>H. Shah, <\/b> None..<br><b>Y. Kinoshita, <\/b> None..<br><b>R. Brody, <\/b> None..<br><b>A. Rubinsteyn, <\/b> None.&nbsp;<br><b>R. Sebra, <\/b> <br><b>GeneDx\/BioReference<\/b> Stock, Stock Option, Other, Consulting or Advisory Role. <br><b>N. Bhardwaj, <\/b> <br><b>Tempest Therapeutics, CureVac, PrimeVax, Novartis, Roche\/Genentech, Boehringer Ingelheim, ROME Therapeutics, Apricity Health, BioNTech SE, BreakBio Corp., Carisma Therapeutics, Genotwin, Gilead Scie<\/b> Other, Scientific advisory. <br><b>Apricity Health, Genotwin, PrimeVax<\/b> Stock. <br><b>Novocure, Celldex, Genentech, Oncovir, Regeneron<\/b> Other, Research Funding. <br><b>M. Galsky, <\/b> <br><b>BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seagen, Incyte, Aileron Therapeutics, Dracen,<\/b> Other, Scientific advisory. <br><b>Icahn School of Medicine at Mt Sinai<\/b> Patent, METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792. <br><b>Rappta Therapeutics<\/b> Stock, Stock Option. <br><b>Genentech\/Roche, AstraZeneca, Merck, Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb<\/b> Other, Research Funding.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10579","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB113","PresenterBiography":null,"PresenterDisplayName":"Nina Bhardwaj, MD;PhD","PresenterKey":"15b2ca69-db5b-41fa-85ed-be6bbbc9051b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB113. Immunogenicity of Atezolizumab plus personalized neoantigen vaccination (PGV-001) in patients with urothelial cancer in adjuvant vs metastatic setting","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Immunogenicity of Atezolizumab plus personalized neoantigen vaccination (PGV-001) in patients with urothelial cancer in adjuvant vs metastatic setting","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-06 Immune monitoring\/clinical correlates,,"},{"Key":"Keywords","Value":"Immune cells,Dendritic cells,Solid tumors,Cancer immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Wang<\/b><sup>1<\/sup>, S. Li<sup>1<\/sup>, M. Wang<sup>1<\/sup>, X. Wang<sup>1<\/sup>, S. Chen<sup>1<\/sup>, Z. Sun<sup>1<\/sup>, X. Ren<sup>2<\/sup>, G. Huang<sup>1<\/sup>, B. Sumer<sup>1<\/sup>, N. Yan<sup>1<\/sup>, Y.-X. Fu<sup>1<\/sup>, J. Gao<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>2<\/sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, China","CSlideId":"","ControlKey":"97ea0d62-c7e1-4364-9e01-8a8217bbcd34","ControlNumber":"10355","DisclosureBlock":"&nbsp;<b>J. Wang, <\/b> None..<br><b>S. Li, <\/b> None..<br><b>M. Wang, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>S. Chen, <\/b> None..<br><b>Z. Sun, <\/b> None..<br><b>X. Ren, <\/b> None..<br><b>G. Huang, <\/b> None..<br><b>B. Sumer, <\/b> None..<br><b>N. Yan, <\/b> None..<br><b>Y. Fu, <\/b> None..<br><b>J. Gao, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10580","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB114","PresenterBiography":null,"PresenterDisplayName":"Jian Wang","PresenterKey":"5340e74e-b6e0-42bd-b8fa-366af65b6ff4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB114. STING licensing of type I dendritic cells potentiates antitumor immunity<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"STING licensing of type I dendritic cells potentiates antitumor immunity<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-07 Immune response to therapies,,"},{"Key":"Keywords","Value":"Akt,Foxp3,Immunotherapy,Lung cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Houry<sup>1<\/sup>, M. Redrado<sup>1<\/sup>, L. Carnevalli<sup>2<\/sup>, S. Barry<sup>3<\/sup>, N. Galan<sup>1<\/sup>, N. Otegui<sup>1<\/sup>, S. Leon<sup>1<\/sup>, L. Montuenga<sup>4<\/sup>, F. Exposito<sup>5<\/sup>, <b>A. Calvo<\/b><sup>4<\/sup>; <br\/><sup>1<\/sup>CIMA, University of Navarra, Pamplona, Spain, <sup>2<\/sup>Oncology R&D, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom, <sup>3<\/sup>Astra Zeneca, UK, Cambridge, United Kingdom, <sup>4<\/sup>University of Navarra, Pamplona, Spain, <sup>5<\/sup>Yale Cancer Center, New Haven, CT","CSlideId":"","ControlKey":"17032b28-693c-445f-9429-f0f050d1ac01","ControlNumber":"9593","DisclosureBlock":"&nbsp;<b>M. Houry, <\/b> None..<br><b>M. Redrado, <\/b> None.&nbsp;<br><b>L. Carnevalli, <\/b> <br><b>Astra Zeneca<\/b> Employee. <br><b>S. Barry, <\/b> <br><b>Astra Zeneca<\/b> Other, Employee.<br><b>N. Galan, <\/b> None..<br><b>N. Otegui, <\/b> None..<br><b>S. Leon, <\/b> None.&nbsp;<br><b>L. Montuenga, <\/b> <br><b>Astra Zeneca<\/b> Grant\/Contract.<br><b>F. Exposito, <\/b> None.&nbsp;<br><b>A. Calvo, <\/b> <br><b>Astra Zeneca<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10581","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB115","PresenterBiography":null,"PresenterDisplayName":"Alfonso Calvo, PhD","PresenterKey":"abd9338d-96da-4c1e-8f69-b66e1f09d184","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB115. Strong antitumor effect elicited by inhibition of AKT or FOXP3 in combination with anti-PD-L1 in <i>Pten<\/i> mutant lung squamous cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Strong antitumor effect elicited by inhibition of AKT or FOXP3 in combination with anti-PD-L1 in <i>Pten<\/i> mutant lung squamous cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-08 Immunomodulatory agents and interventions,,"},{"Key":"Keywords","Value":"Immunotherapy,Immunomodulation,Cancer immunotherapy,Antibody-drug conjugate (ADC),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Temme<\/b><sup>1<\/sup>, A. Hagstotz<sup>1<\/sup>, I. Schau<sup>1<\/sup>, M. Seifert<sup>2<\/sup>, D. Sürün<sup>3<\/sup>, S. Zimmermann<sup>4<\/sup>, F. Buchholz<sup>3<\/sup>, L. Rupp<sup>5<\/sup>, R. Wehner<sup>5<\/sup>, M. Schmitz<sup>5<\/sup>, G. Schackert<sup>1<\/sup>, I. Y. Eyüpoglu<sup>1<\/sup>; <br\/><sup>1<\/sup>Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, Section Experimental Neurosurgery and Tumor Immunology, University Hospital Carl Gustav Carus, Dresden, Germany, <sup>2<\/sup>Technische Universität Dresden, Faculty of Medicine, Institute for Medical Informatics and Biometry, Dresden, Germany, <sup>3<\/sup>Technische Universität Dresden, Medical Faculty and University Hospital Carl Gustav Carus, Medical Systems Biology, Dresden, Germany, <sup>4<\/sup>University of Freiburg, Laboratory for MEMS Applications, IMTEK - Department of Microsystems Engineering, Freiburg, Germany, <sup>5<\/sup>Technische Universität Dresden, Faculty of Medicine, Institute of Immunology, Dresden, Germany","CSlideId":"","ControlKey":"79c3008e-e4c7-483f-9f2d-b65ab8bc5fd3","ControlNumber":"10623","DisclosureBlock":"&nbsp;<b>A. Temme, <\/b> None..<br><b>A. Hagstotz, <\/b> None..<br><b>I. Schau, <\/b> None..<br><b>M. Seifert, <\/b> None..<br><b>D. Sürün, <\/b> None..<br><b>S. Zimmermann, <\/b> None..<br><b>F. Buchholz, <\/b> None..<br><b>L. Rupp, <\/b> None..<br><b>R. Wehner, <\/b> None..<br><b>M. Schmitz, <\/b> None..<br><b>G. Schackert, <\/b> None..<br><b>I. Y. Eyüpoglu, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10582","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB116","PresenterBiography":null,"PresenterDisplayName":"Achim Temme, Dr Rer Nat","PresenterKey":"b777e079-9069-4ac8-b79c-6d5801d3cce7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB116. Antibody-TLR3 agonist-conjugates induce innate immune responses and immune memory eradicating experimental EGFRvIII-positive tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Antibody-TLR3 agonist-conjugates induce innate immune responses and immune memory eradicating experimental EGFRvIII-positive tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-08 Immunomodulatory agents and interventions,,"},{"Key":"Keywords","Value":"Immunotherapy,Immuno-oncology,Cytotoxic T cell,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Dorrier<\/b>, F. Abebe, O. Pak, E. De-Bodene, J. Wang; <br\/>Verimmune Inc., Washington, DC","CSlideId":"","ControlKey":"fe736b3b-2e9d-4db3-a6a4-526f084f7b42","ControlNumber":"9587","DisclosureBlock":"<b>&nbsp;C. Dorrier, <\/b> <br><b>VerImmune<\/b> Employment, Stock Option. <br><b>F. Abebe, <\/b> <br><b>VerImmune<\/b> Employment, Stock Option. <br><b>O. Pak, <\/b> <br><b>VerImmune<\/b> Employment, Stock Option. <br><b>E. De-Bodene, <\/b> <br><b>VerImmune<\/b> Employment, Stock Option. <br><b>J. Wang, <\/b> <br><b>VerImmune<\/b> Employment, Stock Option, Other, Joshua Wang is the Founder of VerImmune Inc, and has an equity ownership interest and stock options in VerImmune Inc.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10583","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB117","PresenterBiography":null,"PresenterDisplayName":"Cayce Dorrier, PhD","PresenterKey":"1f907e85-4cf6-48d6-9857-a8b6029c4a91","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB117. Virus-inspired Particles (ViPs) harnessing cytomegalovirus immune memory for local and systemic cancer immunotherapy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Virus-inspired Particles (ViPs) harnessing cytomegalovirus immune memory for local and systemic cancer immunotherapy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-08 Immunomodulatory agents and interventions,,"},{"Key":"Keywords","Value":"Interleukin-2,Immunotherapy,Immunomodulation,Melanoma\/skin cancers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S.-B. Shin, J. Kim, <b>J. Choi<\/b>, S. Jeong, Y. Kim, J. Byun, S. Bae, D. Kim, I. Choi; <br\/>Hanmi Pharmaceutical Co., Ltd., Hwaseung-si, Korea, Republic of","CSlideId":"","ControlKey":"49f04653-15f4-4bd4-b421-516a29a6d1e0","ControlNumber":"10273","DisclosureBlock":"&nbsp;<b>S. Shin, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>J. Choi, <\/b> None..<br><b>S. Jeong, <\/b> None..<br><b>Y. Kim, <\/b> None..<br><b>J. Byun, <\/b> None..<br><b>S. Bae, <\/b> None..<br><b>D. Kim, <\/b> None..<br><b>I. Choi, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10584","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB118","PresenterBiography":null,"PresenterDisplayName":"Jaehyuk Choi, PhD","PresenterKey":"bb1577ff-0d24-40dc-bc85-6269e2ce5dda","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB118. HM16390, a novel long-acting IL-2 analog with fine-tuned binding affinities to IL-2 receptor subunits for favorable safety profile, exhibits potent tumor killing effect in the various tumor syngeneic models","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"HM16390, a novel long-acting IL-2 analog with fine-tuned binding affinities to IL-2 receptor subunits for favorable safety profile, exhibits potent tumor killing effect in the various tumor syngeneic models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-08 Immunomodulatory agents and interventions,,"},{"Key":"Keywords","Value":"Interleukin-2,Tumor microenvironment,Cold tumor,Immune modulator,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Jeong, Y. Kim, <b>J. Byun<\/b>, J. Kim, J. Choi, S. Bae, D. Kim, I. Choi; <br\/>Hanmi Pharmaceutical Co., Ltd., Hwaseong-si, Korea, Republic of","CSlideId":"","ControlKey":"ae608531-2008-4464-98a5-cfcd77acaa03","ControlNumber":"10569","DisclosureBlock":"&nbsp;<b>S. Jeong, <\/b> None..<br><b>Y. Kim, <\/b> None..<br><b>J. Byun, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>J. Choi, <\/b> None..<br><b>S. Bae, <\/b> None..<br><b>D. Kim, <\/b> None..<br><b>I. Choi, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10585","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB119","PresenterBiography":"","PresenterDisplayName":"Jooyun Byun, PhD","PresenterKey":"20f8bf36-d066-4b99-9291-a66871892406","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB119. The immune-modulation of HM16390, firing up the poor tumor microenvironment to induce a potent anti-tumor efficacy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The immune-modulation of HM16390, firing up the poor tumor microenvironment to induce a potent anti-tumor efficacy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-10 Modifiers of the tumor microenvironment,,"},{"Key":"Keywords","Value":"Adoptive cell therapy,Antitumor activity,Tumor microenvironment,Innate immunity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>X. Wang<\/b>, A. J. Hou, M. A. Christopher, Y. Bulliard, J. S. Damiano; <br\/>Appia Bio, Culver City, CA","CSlideId":"","ControlKey":"8e306bac-a2c2-4e53-83d0-fbc2dccf6af3","ControlNumber":"10753","DisclosureBlock":"<b>&nbsp;X. Wang, <\/b> <br><b>Appia Bio<\/b> Employment, Stock. <br><b>A. J. Hou, <\/b> <br><b>Appia Bio<\/b> Employment, Stock Option. <br><b>M. A. Christopher, <\/b> <br><b>Appia Bio<\/b> Independent Contractor, Stock Option. <br><b>Y. Bulliard, <\/b> <br><b>Appia Bio<\/b> Employment. <br><b>J. S. Damiano, <\/b> <br><b>Appia Bio<\/b> Employment, Stock Option.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10586","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB120","PresenterBiography":null,"PresenterDisplayName":"Xi Wang","PresenterKey":"8a6596a3-da81-40cf-9e8d-47af3317f6ac","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB120. Stem cell-derived ACUA CAR-NKT allogeneic cell therapies harness orthogonal mechanisms of action for the treatment of solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Stem cell-derived ACUA CAR-NKT allogeneic cell therapies harness orthogonal mechanisms of action for the treatment of solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-10 Modifiers of the tumor microenvironment,,"},{"Key":"Keywords","Value":"Colorectal cancer,Endothelial cells,Paracrine,Immunomodulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"F. Fan, L. M. Ellis, <b>R. Bhattacharya<\/b>; <br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"de50d8fb-41cd-4e50-aef4-996b74311f29","ControlNumber":"10777","DisclosureBlock":"&nbsp;<b>F. Fan, <\/b> None.&nbsp;<br><b>L. M. Ellis, <\/b> <br><b>Oncohost<\/b> Other, Consultant. <br><b>Actuate Therapeutics<\/b> Consultant. <br><b>New Beta Innovations<\/b> Data Monitoring Committee. <br><b>Fibrogen<\/b> Data Monitoring Committee member. <br><b>R. Bhattacharya, <\/b> <br><b>BioMedValley Discoveries<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10587","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB121","PresenterBiography":"","PresenterDisplayName":"Rajat Bhattacharya, PhD","PresenterKey":"209b6011-f40a-454c-884a-251898e1b09b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB121. Endothelial cells mediated paracrine signaling alters immune cell modulators on colorectal cancer cells","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Endothelial cells mediated paracrine signaling alters immune cell modulators on colorectal cancer cells","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Antibody,T cell engager,Solid tumors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Vijayaraghavan<\/b>, P. Seth, A. Winkis, K. Chevalier, A. Marthaler, K. Sproesser, V. Torti, N. Shah, E. Lacy, A.-L. Frisk, H. Deutsch, G. Chu, M. Sharp, J. Pabalan, C. Tilegenova, K. Thorton, J. Lauring, B. Mattson, K. Tian, J. Kinyamu-Akunda, L. Lenox, W. Cheung, S. Moores, S. Laquerre; <br\/>J&J Innovative Medicine, Spring House, PA","CSlideId":"","ControlKey":"e748c3b3-a5a8-4bca-be3d-deb2a213a961","ControlNumber":"9736","DisclosureBlock":"<b>&nbsp;S. Vijayaraghavan, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment, Stock Option. <br><b>P. Seth, <\/b> <br><b>J&J<\/b> Employment, Stock Option. <br><b>Zaiming Inc \/ Simcere Pharma<\/b> Employment. <br><b>A. Winkis, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>K. Chevalier, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>A. Marthaler, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>K. Sproesser, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>V. Torti, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>N. Shah, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>E. Lacy, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>A. Frisk, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>H. Deutsch, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>G. Chu, <\/b> <br><b>J&j Innovative Medicine<\/b> Employment. <br><b>M. Sharp, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>J. Pabalan, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>C. Tilegenova, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>K. Thorton, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>J. Lauring, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>B. Mattson, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>K. Tian, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>J. Kinyamu-Akunda, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>L. Lenox, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>W. Cheung, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>S. Moores, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment. <br><b>S. Laquerre, <\/b> <br><b>J&J Innovative Medicine<\/b> Employment.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10588","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB122","PresenterBiography":null,"PresenterDisplayName":"Smruthi Vijayaraghavan, PhD","PresenterKey":"c5a855bf-8ff9-4a5d-b2ce-4b004e23c1d3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB122. JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Cancer associated fibroblasts,Bispecific antibody,Antigen presentation,B cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Lewandowska, F. Demircioglu, L. Penfold, R. B. Riddle, S. Sirohi, F. Laurent, R. Brown, S. Bains, D. Bevan, E. Stanley, J. Pignatelli, <b>J. W. Legg<\/b>, R. Jupp; <br\/>Mestag Therapeutics, Cambridge, United Kingdom","CSlideId":"","ControlKey":"18525692-41f0-45d0-8635-b12ede12ef77","ControlNumber":"10294","DisclosureBlock":"<b>&nbsp;M. Lewandowska, <\/b> <br><b>Mestag Threapeutics<\/b> Employment, Stock Option, Patent. <br><b>F. Demircioglu, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>L. Penfold, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>R. B. Riddle, <\/b> <br><b>Mestag Therapeutics<\/b> Employment. <br><b>S. Sirohi, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>F. Laurent, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>R. Brown, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>Sanofi<\/b> Stock. <br><b>S. Bains, <\/b> <br><b>Mestag Therapeutics<\/b> Employment. <br><b>D. Bevan, <\/b> <br><b>Mestag Therapeutics<\/b> Employment. <br><b>E. Stanley, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>J. Pignatelli, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option. <br><b>J. W. Legg, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option, Patent. <br><b>Astra Zeneca<\/b> Stock. <br><b>R. Jupp, <\/b> <br><b>Mestag Therapeutics<\/b> Employment, Stock Option, Patent.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10589","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB123","PresenterBiography":null,"PresenterDisplayName":"James Legg, PhD","PresenterKey":"c7aa1669-266a-42b1-8199-655a25a3f713","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB123. Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),NaPi2b,solid tumors,Microbial Transglutaminase (MTG),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>I. Attinger-Toller<\/b>, P. Probst, L. Kallenberger, E. Renard, R. Bertrand, R. Fay, R. Santimaria, P. Maurhofer, D. Grabulovski, B. Schlereth, P. R. Spycher; <br\/>Araris Biotech AG, Au, Switzerland","CSlideId":"","ControlKey":"95b90cd1-50da-4bd8-8cce-5fadaff2c288","ControlNumber":"10897","DisclosureBlock":"&nbsp;<b>I. Attinger-Toller, <\/b> None..<br><b>P. Probst, <\/b> None..<br><b>L. Kallenberger, <\/b> None..<br><b>E. Renard, <\/b> None..<br><b>R. Bertrand, <\/b> None..<br><b>R. Fay, <\/b> None..<br><b>R. Santimaria, <\/b> None..<br><b>P. Maurhofer, <\/b> None..<br><b>D. Grabulovski, <\/b> None..<br><b>B. Schlereth, <\/b> None..<br><b>P. R. Spycher, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10590","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB124","PresenterBiography":null,"PresenterDisplayName":"Isabella Attinger-Toller, PhD","PresenterKey":"9c15e9d9-6b3f-4cfb-8216-bed245c3161e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB124. Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Hepatocellular carcinoma,Tumor initiating cells,T cell engager,Bispecific antibody,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W. Ma<sup>1<\/sup>, N. Wang<sup>1<\/sup>, H. Choi<sup>1<\/sup>, L. Ziying<sup>1<\/sup>, N. Fajardo<sup>1<\/sup>, R. Ilaga<sup>1<\/sup>, R. Machida<sup>1<\/sup>, Z. Lin<sup>1<\/sup>, A. Ramrakhiani<sup>1<\/sup>, Y. Y. Chen<sup>2<\/sup>, L. Sher<sup>1<\/sup>, S. M. Tahara<sup>1<\/sup>, <b>K. Machida<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Keck School of Medicine of USC, Los Angeles, CA, <sup>2<\/sup>UCLA, Los Angeles, CA","CSlideId":"","ControlKey":"29f0c5d8-e968-453a-ac2c-300b8b7dd817","ControlNumber":"9517","DisclosureBlock":"&nbsp;<b>W. Ma, <\/b> None..<br><b>N. Wang, <\/b> None..<br><b>H. Choi, <\/b> None..<br><b>L. Ziying, <\/b> None..<br><b>N. Fajardo, <\/b> None..<br><b>R. Ilaga, <\/b> None..<br><b>R. Machida, <\/b> None..<br><b>Z. Lin, <\/b> None..<br><b>A. Ramrakhiani, <\/b> None..<br><b>Y. Y. Chen, <\/b> None..<br><b>L. Sher, <\/b> None..<br><b>S. M. Tahara, <\/b> None..<br><b>K. Machida, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10591","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB125","PresenterBiography":null,"PresenterDisplayName":"Keigo Machida, PhD","PresenterKey":"60a58db7-0901-4789-b053-16907ae52b82","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB125. Tri-specific T cell engager targeting of selective surface cancer-selective ligands recruits both T cells and APC targeting of cancer neoantigens of tumor-initiating stem-like cells","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tri-specific T cell engager targeting of selective surface cancer-selective ligands recruits both T cells and APC targeting of cancer neoantigens of tumor-initiating stem-like cells","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"T cell engager,ROR1,Breast cancer,Ovarian cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Danqing Wu<sup>1<\/sup>, Shiyong Gong<sup>1<\/sup>, Xuan Wu<sup>1<\/sup>, Gaowa Naren<sup>1<\/sup>, Liqin Dong<sup>1<\/sup>, Stephan Lensky<sup>2<\/sup>, <b>Chengbin Wu<\/b><sup>1<\/sup><br><br\/><sup>1<\/sup>EpimAb Biotherapeutics Co., Ltd., Shanghai, China,<sup>2<\/sup>EpimAb USA LLC, New Braintree, MA","CSlideId":"","ControlKey":"ed95ff2b-5b0d-4310-b6bc-73977ed0016f","ControlNumber":"9859","DisclosureBlock":"<b>&nbsp;D. Wu, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment. <br><b>S. Gong, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment. <br><b>X. Wu, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment. <br><b>G. Naren, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment. <br><b>L. Dong, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment. <br><b>S. Lensky, <\/b> <br><b>EpimAb<\/b> Employment, Stock Option, Other, Employee in Executive Management. <br><b>C. Wu, <\/b> <br><b>EpimAb Biotherapeutics Co., Ltd.<\/b> Employment.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10592","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB126","PresenterBiography":null,"PresenterDisplayName":"Chengbin Wu, BSc, MSc, PhD","PresenterKey":"ec7b8d0b-4a4e-4e93-af08-3dda89dfdebf","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB126. Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Bispecific antibody,Folate receptor,Patient-derived xenograft (PDX),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Zhang, C. Shang, <b>C. Guo<\/b>, Y. Yang; <br\/>Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China","CSlideId":"","ControlKey":"b4cd723c-83bb-42bf-b902-97a98112e148","ControlNumber":"10526","DisclosureBlock":"&nbsp;<b>Y. Zhang, <\/b> None..<br><b>C. Shang, <\/b> None..<br><b>C. Guo, <\/b> None..<br><b>Y. Yang, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10593","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB127","PresenterBiography":"","PresenterDisplayName":"Qingcong Lin, PhD","PresenterKey":"acbdaa49-9fe2-4a5c-85ab-19b084bc2408","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB127. A first-in-class bispecific ADC targeting FORL1 and MUC1 exhibits promising anti-tumor activity in a FOLR1<sup>low<\/sup> xenograft model","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-class bispecific ADC targeting FORL1 and MUC1 exhibits promising anti-tumor activity in a FOLR1<sup>low<\/sup> xenograft model","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"T cell engager,Multiple myeloma,BCMA,Tumor-associated antigen (TAA),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Tan, X. Li, F. Yu, J. Xu, Z. Qian, Y. Cao, X. Yang, Q. Du, F. Peng, <b>S. Han<\/b>, Q. Ding; <br\/>Genor Biopharma Co. Ltd., Shanghai, China","CSlideId":"","ControlKey":"d13d1ce7-94e7-4378-922a-808f7b247e8a","ControlNumber":"10613","DisclosureBlock":"&nbsp;<b>Y. Tan, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>F. Yu, <\/b> None..<br><b>J. Xu, <\/b> None..<br><b>Z. Qian, <\/b> None..<br><b>Y. Cao, <\/b> None..<br><b>X. Yang, <\/b> None..<br><b>Q. Du, <\/b> None..<br><b>F. Peng, <\/b> None..<br><b>S. Han, <\/b> None..<br><b>Q. Ding, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10594","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB128","PresenterBiography":null,"PresenterDisplayName":"Shuhua Han, PhD","PresenterKey":"14a1be53-9d14-47de-b71c-91fee7714ba9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB128. A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"Multiple myeloma,hematologic malignancies,CD38,CD47,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W. Tian, S. Li, D. Chen, Y. Yang, H. Guo, D. Liu, R. Zhang, <b>F. Zhang<\/b>; <br\/>ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China","CSlideId":"","ControlKey":"2a0273fa-e0e6-4b3c-b1e7-fecbad5b9147","ControlNumber":"9713","DisclosureBlock":"<b>&nbsp;W. Tian, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>S. Li, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>D. Chen, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>Y. Yang, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>H. Guo, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>D. Liu, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>R. Zhang, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>F. Zhang, <\/b> <br><b>ImmuneOnco Biopharmaceuticals<\/b> Employment.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10595","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB129","PresenterBiography":null,"PresenterDisplayName":"Fan Zhang, PhD","PresenterKey":"6b980082-7844-46fe-81ea-63d5b50bd452","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB129. Preclinical development of a bispecific antibody-trap selectively targeting CD38 and CD47 for treating hematologic malignancies","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preclinical development of a bispecific antibody-trap selectively targeting CD38 and CD47 for treating hematologic malignancies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"G-protein-coupled receptors (GPCR),Antibody-dependent cellular cytotoxicity (ADCC),Regulatory T cells,Human monoclonal antibodies,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H. Liang<sup>1<\/sup>, Y. Guo<sup>1<\/sup>, M. Yin<sup>1<\/sup>, A. Kawagishi<sup>2<\/sup>, T. Terada<sup>2<\/sup>, Y. Kihara<sup>2<\/sup>, T. Kanke<sup>2<\/sup>, <b>C. Guo<\/b><sup>1<\/sup>, W. An<sup>1<\/sup>, Y. Yang<sup>1<\/sup>; <br\/><sup>1<\/sup>Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China, <sup>2<\/sup>LiberoThera Co., Ltd., Tokyo, Japan","CSlideId":"","ControlKey":"a350dedd-0f39-49e2-b6c2-a305030bfacb","ControlNumber":"10527","DisclosureBlock":"&nbsp;<b>H. Liang, <\/b> None..<br><b>Y. Guo, <\/b> None..<br><b>M. Yin, <\/b> None..<br><b>A. Kawagishi, <\/b> None..<br><b>T. Terada, <\/b> None..<br><b>Y. Kihara, <\/b> None..<br><b>T. Kanke, <\/b> None..<br><b>C. Guo, <\/b> None..<br><b>W. An, <\/b> None..<br><b>Y. Yang, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10596","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB130","PresenterBiography":"","PresenterDisplayName":"Qingcong Lin, PhD","PresenterKey":"acbdaa49-9fe2-4a5c-85ab-19b084bc2408","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB130. Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-11 Therapeutic antibodies, including engineered antibodies,,"},{"Key":"Keywords","Value":"CD73,DFC,Inhibitors,Internalization,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. Abelovski<\/b>, N. Dedeic, S. Döhrmann, J. Levin, A. Almaguer, D. Zuill, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt, G. Hough, J. B. Locke, J. N. Cole, L. W. Tari; <br\/>Cidara Therapeutics, Inc., San Diego, CA","CSlideId":"","ControlKey":"423bc5bd-f489-4607-a189-f23b389c8810","ControlNumber":"10725","DisclosureBlock":"&nbsp;<b>E. Abelovski, <\/b> None..<br><b>N. Dedeic, <\/b> None..<br><b>S. Döhrmann, <\/b> None..<br><b>J. Levin, <\/b> None..<br><b>A. Almaguer, <\/b> None..<br><b>D. Zuill, <\/b> None..<br><b>J. Fortier, <\/b> None..<br><b>Q. Zhao, <\/b> None..<br><b>M. Hernandez, <\/b> None..<br><b>K. Amundson, <\/b> None..<br><b>M. Moniz, <\/b> None..<br><b>H. Chen, <\/b> None..<br><b>D. Panickar, <\/b> None..<br><b>T. Lam, <\/b> None..<br><b>T. Brady, <\/b> None..<br><b>A. Borchardt, <\/b> None..<br><b>G. Hough, <\/b> None..<br><b>J. B. Locke, <\/b> None..<br><b>J. N. Cole, <\/b> None..<br><b>L. W. Tari, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10597","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB131","PresenterBiography":null,"PresenterDisplayName":"Elizabeth Abelovski, BS","PresenterKey":"a66a592f-bed6-4378-b799-4529877079eb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB131. CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"602","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 2","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization","Topics":null,"cSlideId":""}]